Stryker completes acquisition of NOVADAQ Technologies Inc.
September 01 2017 - 8:00AM
Kalamazoo, Michigan - September 1, 2017 - Stryker
Corporation (NYSE:SYK) announced today the completion of its
previously announced acquisition of NOVADAQ Technologies Inc.
NOVADAQ is a leading developer of fluorescence imaging technology
that provides surgeons with visualization of blood flow in vessels,
and related tissue perfusion in cardiac, cardiovascular,
gastrointestinal, plastic, microsurgical, and reconstructive
procedures.
As indicated in the June 19, 2017 press release,
the transaction is expected to be dilutive to Stryker's 2017
adjusted net earnings per diluted share by $0.03 - $0.05.
Forward-looking
statements
This press release contains information that
includes or is based on forward-looking statements within the
meaning of the federal securities law that are subject to various
risks and uncertainties that could cause our actual results to
differ materially from those expressed or implied in such
statements. Such factors include, but are not limited to: weakening
of economic conditions that could adversely affect the level of
demand for our products; pricing pressures generally, including
cost-containment measures that could adversely affect the price of
or demand for our products; changes in foreign exchange markets;
legislative and regulatory actions; unanticipated issues arising in
connection with clinical studies and otherwise that affect U.S.
Food and Drug Administration approval of new products; potential
supply disruptions; changes in reimbursement levels from
third-party payors; a significant increase in product liability
claims; the ultimate total cost with respect to the Rejuvenate and
ABG II matter; the impact of investigative and legal proceedings
and compliance risks; resolution of tax audits; the impact of the
federal legislation to reform the United States healthcare system;
changes in financial markets; changes in the competitive
environment; our ability to integrate acquisitions; and our ability
to realize anticipated cost savings. Additional information
concerning these and other factors is contained in our filings with
the U.S. Securities and Exchange Commission, including our Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q.
Stryker is one of the world's leading medical
technology companies and, together with our customers, we are
driven to make healthcare better. The Company offers a diverse
array of innovative products and services in Orthopaedics,
Medical and Surgical, and Neurotechnology and Spine that help
improve patient and hospital outcomes. Stryker is active in
over 100 countries around the world. Please contact us for
more information at www.stryker.com.
Contacts
For investor inquiries please
contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 or
katherine.owen@stryker.com
For media inquiries please
contact:
Yin Becker, Stryker Corporation, 269-385-2600 or
yin.becker@stryker.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Stryker Corporation via Globenewswire
Stryker (NYSE:SYK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Stryker (NYSE:SYK)
Historical Stock Chart
From Sep 2023 to Sep 2024